Details:
The proceeds will fund the clinical study programs for PUR0110 (thykamine) in particular the phase 2/3 program in pediatric atopic dermatitis, the phase 2 programs in radiodermatitis associated with radiotherapy and in Hand and Foot Syndrome and associated with chemotherapy.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: TSX Venture Exchange
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement May 19, 2023
Details:
Thykamine (PUR0110) is a highly innovative product for the prevention and treatment of health conditions related to inflammation and oxidative stress including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune disorders.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 12, 2022
Details:
In the study, a significantly greater proportion of adult patients treated with Thykamine™ (PUR0110) cream 0.10% achieved an IGA of clear/almost clear and at least a 2-grade improvement from baseline in IGA (30.8%) compared to placebo (6.7%; P =.014).
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 06, 2022
Details:
The benefit of PUR0110 (Thykamine) cream 0.10% was supported by a statistically significant effect on the primary and secondary endpoints of Body Surface Area (BSA), pruritis, and Patient-Oriented Eczema Measure score (POEM).
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2022
Details:
EB01, is an investigational medicine that contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor met primary efficacy endpoint, which is the mean percent change from baseline on the CDSI at day 29.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: JSS Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 01, 2021
Details:
EB01 is designed to inhibit the inflammatory process at its inception rather than after inflammation has occurred, the company believes that the drug could potentially exert a powerful anti-inflammatory effect without the safety concerns of steroids.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 03, 2021
Details:
EB01 contains a non-steroidal anti-inflammatory compound known as an sPLA2 inhibitor. Edesa reported that all 46 subjects in the first cohort have been randomized and dosed with either Edesa's EB01 topical treatment or a placebo cream.
Lead Product(s): EB01
Therapeutic Area: Dermatology Product Name: EB01
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: JSS Medical Research
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
According to the results from the study, Thykamine at 0.1% showed significant improvement in skin clearance versus placebo at all measured timelines, thereby meeting the primary endpoint. It showed a fast onset of the therapeutic effect.
Lead Product(s): Thykamine
Therapeutic Area: Dermatology Product Name: PUR0110
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: PurGenesis Technologies
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 18, 2021